SS-31 Peptide (Elamipretide): Mechanism, Trials, and Honest Status

SS-31 is the mitochondrial peptide with the best evidence behind it, and that is because it went through real clinical trials rather than because the research community likes it. It is also the compound whose trial record is most often summarised dishonestly, because those trials were run in people with inherited mitochondrial disease and several of them missed their primary endpoints.

Both of those things are true at once, and holding them together is the only honest way to read this compound. What follows is the mechanism, what each trial programme actually reported, what the research community claims, and where the gap between the two sits. Research use only, and nothing here is medical advice or a dosing recommendation.

What SS-31 Is

SS-31 is a synthetic tetrapeptide, four amino acids, also known as elamipretide and earlier as Bendavia and MTP-131. The SS designation comes from the Szeto-Schiller series of cell penetrating peptides it belongs to.

Its defining structural feature is an alternating aromatic and cationic motif, which lets it cross cell membranes and concentrate in the inner mitochondrial membrane without depending on the membrane potential. That last detail matters more than it sounds: most cationic molecules accumulate in mitochondria because they are pulled in by the potential gradient, which means they stop working in exactly the damaged mitochondria you would want to target. SS-31 does not have that problem.

Once there, it associates with cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin holds the cristae folds in shape and organises the electron transport chain complexes that sit in them. When cardiolipin is damaged or abnormal, the membrane leaks, electron transport becomes inefficient, less ATP comes out per unit of substrate, and more reactive oxygen species come out instead. Stabilising cardiolipin addresses the structural fault rather than pushing harder on a broken system, which is a genuinely different approach from anything else marketed for mitochondrial function.

The Trial Record

Elamipretide has been through more clinical development than any other peptide in this category, run by Stealth BioTherapeutics across several unrelated indications. The results are mixed in a specific and instructive way.

The Barth syndrome programme is the one that got furthest. Barth is a rare X linked disorder in which cardiolipin remodelling itself is broken, which makes it the single population where a cardiolipin stabiliser has the tightest possible mechanistic rationale. That programme is also the only one that produced a regulatory approval, granted in 2025 on a narrow label for that one rare disease. It is worth being precise about what that means: a compound approved for an inherited cardiolipin disorder in a patient population numbering in the hundreds is not a compound approved for fatigue, ageing, or training recovery, and the approval carries no implication about any of those.

The primary mitochondrial myopathy failure is the more informative result for everybody else. That trial tested exactly the hypothesis the research community is interested in, that stabilising mitochondrial membranes improves functional capacity, in the population most likely to respond, and the six minute walk distance endpoint did not separate from placebo at 24 weeks. A clean mechanism does not guarantee a clinical effect. That is the lesson, and it applies with more force, not less, to people whose mitochondria are working normally to begin with.

What the Research Community Claims

The claims in circulation are energy, endurance, recovery, cognitive clarity and general anti ageing benefit, usually stated with a reference to the cardiolipin mechanism and no reference to the trial outcomes.

There is a coherent hypothesis underneath. Cardiolipin content and composition do change with age, mitochondrial efficiency does decline, and a molecule that stabilises the structure is a plausible intervention on paper. Preclinical work in ageing animals has reported improvements in muscle energetics and mitochondrial function, which is where most of the enthusiasm originates.

The gap is that every one of those studies is either preclinical or conducted in people with a documented mitochondrial defect. There is no trial of elamipretide in healthy adults for energy, performance or longevity, and the trials that came closest to testing the general hypothesis in humans did not hit their endpoints. Anyone using it is extrapolating across two separate leaps: from animals to humans, and from diseased mitochondria to healthy ones. The peptides for energy comparison ranks it against MOTS-c and NAD+ on exactly this basis, and MOTS-c is the compound most often run alongside it, acting through AMPK rather than through membrane structure.

The longevity framing deserves its own caution. Mitochondrial decline is one of several recognised hallmarks of ageing, and addressing a hallmark is not the same as extending healthspan. The longevity peptides page covers how little of that category has human outcome data of any kind.

Dosing Patterns Reported in Research Settings

This section describes what is reported, not what anyone should do. There is no established protocol for SS-31 outside a clinical trial, and no dose finding work in healthy subjects exists.

The disease trials used 40mg daily by subcutaneous injection, given continuously over months. That is a substantial daily dose of a peptide, and it is the figure most often quoted second hand without the context that it came from supervised trials in patients with a defined pathology.

Protocols reported in research forums run considerably lower and shorter, typically in the low milligrams per day in blocks of four to six weeks, sometimes split across the day and sometimes combined with MOTS-c or an NAD+ precursor. Those figures are extrapolations from the trial dosing, scaled down by people who considered the trial dose excessive for a non patient, rather than numbers derived from any study. Reported is the strongest word that applies to them. Daily subcutaneous injection over weeks is also a meaningful practical commitment, which is the part usually left out of the summary.

Reconstitution and Storage

SS-31 arrives as a lyophilised powder and follows standard peptide handling. Bacteriostatic water rather than sterile water for a vial that will be used more than once, added slowly down the side of the vial rather than directly onto the powder, then swirled gently and never shaken. The full technique is in the reconstitution guide.

Storage follows the same rules as other lyophilised peptides: cold and dark for the dry powder, refrigerated once reconstituted, and a working assumption of around 28 days in solution rather than an indefinite shelf life. The storage and stability guide covers what actually degrades and how fast.

The table below is arithmetic on concentrations, included because the conversion is where most handling errors happen. It is not a dosing recommendation and the dose column is illustrative only.

Units here are marks on a U-100 insulin syringe, where one unit is 0.01mL. Concentration is vial milligrams divided by millilitres of water, volume is dose divided by concentration, and units are volume multiplied by 100. Reconstituting too thin is the error worth avoiding, because it pushes a single draw past the end of the barrel. Any vial and water combination can be checked against the peptide reconstitution calculator.

Side Effect Reports

The trial safety record is the useful source here, because it covers months of daily exposure in supervised conditions.

• Injection site reactions. By far the most common finding, and unsurprising given daily subcutaneous administration over months. Redness, itching and induration at the site, generally mild and manageable by rotating sites.
• Gastrointestinal complaints. Nausea and diarrhoea reported at modest rates, not at the level the incretin compounds produce.
• Headache and dizziness. Reported, mild, and at rates that do not separate cleanly from placebo in the smaller trials.
• Nothing that stopped the programmes. The trials that failed did so on efficacy endpoints, not on safety. That is a genuine point in the compound's favour and it is worth stating alongside the efficacy record rather than instead of it.

What none of that covers is unsupervised use at improvised doses in healthy adults, which is a different exposure profile in a different population with no safety data attached.

Honest Status

SS-31 sits in an unusual position. It has more clinical development behind it than any comparable research peptide, a mechanism that is specific and physically well described rather than hand waved, and a safety record built on months of supervised daily dosing. It also has a string of missed primary endpoints in the exact populations where the mechanism should have shown up most clearly, and zero data in anyone healthy.

Whether that adds up to a reason to use it depends entirely on what you were expecting. As the best evidenced compound in a category where the alternative evidence base is rodent studies and forum reports, it is defensible. As something likely to produce a noticeable change in energy in a person whose mitochondria are working normally, the trial record argues against it more than for it.

Key Takeaways

• SS-31, elamipretide, is a four amino acid peptide that concentrates in the inner mitochondrial membrane and binds cardiolipin
• It stabilises cristae structure rather than stimulating a pathway, which is a genuinely distinct mechanism
• The Barth syndrome programme produced a narrow approval in 2025 for that single rare disease and nothing beyond it
• The phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoints
• No trial has ever tested it in healthy adults for energy, performance or longevity
• Trial dosing was 40mg daily subcutaneously; forum protocols run far lower and are extrapolations, not findings
• Injection site reactions are the dominant reported side effect, and the failed trials failed on efficacy rather than safety
• This is research use information and none of it is medical advice

Frequently Asked Questions

What is SS-31 peptide?

SS-31 is a synthetic four amino acid peptide also known as elamipretide, and earlier as Bendavia and MTP-131. Its alternating aromatic and cationic structure lets it cross cell membranes and concentrate in the inner mitochondrial membrane without depending on the membrane potential, which means it still reaches damaged mitochondria. There it binds cardiolipin, the phospholipid that holds cristae structure and organises the electron transport chain.

What did the elamipretide trials actually show?

A mixed record. The phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoints at 24 weeks. The acute myocardial infarction and later retinal programmes also missed their primary endpoints. The Barth syndrome programme missed its primary endpoints in the blinded crossover phase but reported improvement in walk distance and muscle strength in the open label extension, and it is the only programme that produced a regulatory approval, granted in 2025 on a narrow label for that single rare disease.

What SS-31 dosing is reported in research settings?

The clinical trials used 40mg daily by subcutaneous injection, given continuously over months in supervised conditions. Protocols reported in research forums run considerably lower and shorter, typically low milligrams per day in blocks of four to six weeks. Those forum figures are scaled down extrapolations from the trial dose rather than findings from any study, and no dose finding work has ever been done in healthy subjects. This is a description of what is reported, not a recommendation.

How is SS-31 reconstituted and stored?

It arrives as a lyophilised powder and follows standard peptide handling: bacteriostatic water rather than sterile water for a multi use vial, added slowly down the side of the vial rather than directly onto the powder, then swirled gently and never shaken. Store the dry powder cold and dark, refrigerate once reconstituted, and work on an assumption of around 28 days in solution rather than an indefinite shelf life.

Are there side effects reported with SS-31?

Injection site reactions are by far the most common, which is unsurprising for a compound given by daily subcutaneous injection over months. Redness, itching and induration at the site were generally mild and managed by rotating sites. Gastrointestinal complaints, headache and dizziness were reported at modest rates. Notably, the trials that failed did so on efficacy endpoints rather than on safety. None of that safety record covers unsupervised use at improvised doses in healthy adults.